Response of Cutaneous Metastases from Breast Cancer to Capecitabine
2008
Response of Cutaneous Metastases from Breast Cancer to Capecitabine
Sample size: 2
publication
Evidence: low
Author Information
Author(s): Sideras Kostandinos, Zahasky Katie M., Kaur Judith S.
Primary Institution: Mayo Clinic College of Medicine
Conclusion
The two patients treated with capecitabine showed a significant response with resolution of their skin lesions lasting over a year.
Supporting Evidence
- Capecitabine has shown a response rate ranging from 15% to 28% in metastatic breast cancer.
- Complete response rates for capecitabine in metastatic breast cancer range from 1% to 4%.
- Patients with a single cutaneous lesion have a better prognosis than those with multiple metastatic sites.
Takeaway
Two women with skin cancer from breast cancer got better after taking a medicine called capecitabine, and their skin problems went away for a long time.
Methodology
Case reports of two patients treated with capecitabine for cutaneous metastases from breast cancer.
Limitations
The study is based on only two case reports, limiting generalizability.
Participant Demographics
Two female patients, aged 82 and 61, with a history of breast cancer.
Want to read the original?
Access the complete publication on the publisher's website